Cargando…
CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
OBJECTIVE: Neurosurgery (NS) is an essential modality for large brain metastases (BM). As an adjuvant treatment, stereotactic radiosurgery (SRS) reduces neurocognitive toxicity without affecting post-treatment overall survival (OS) compared to whole brain radiation therapy. Pachymeningeal failure (P...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354221/ http://dx.doi.org/10.1093/noajnl/vdac078.040 |
_version_ | 1784763018075176960 |
---|---|
author | Kalyvas, Aristotelis Gutierrez-Valencia, Enrique Weiss, Jessica O’ Halloran, Philip J Mohan, Nilesh Wong, Christine Conrad, Tatiana Millar, Barbara-Ann Laperriere, Normand Bernstein, Mark Zadeh, Gelareh Shultz, David Kongkham, Paul |
author_facet | Kalyvas, Aristotelis Gutierrez-Valencia, Enrique Weiss, Jessica O’ Halloran, Philip J Mohan, Nilesh Wong, Christine Conrad, Tatiana Millar, Barbara-Ann Laperriere, Normand Bernstein, Mark Zadeh, Gelareh Shultz, David Kongkham, Paul |
author_sort | Kalyvas, Aristotelis |
collection | PubMed |
description | OBJECTIVE: Neurosurgery (NS) is an essential modality for large brain metastases (BM). As an adjuvant treatment, stereotactic radiosurgery (SRS) reduces neurocognitive toxicity without affecting post-treatment overall survival (OS) compared to whole brain radiation therapy. Pachymeningeal failure (PMF) beyond the SRS field is a relatively newly described entity, distinct from classical leptomeningeal failure (LMF), and unique to postoperative patients treated with adjuvant SRS. We sought to identify risk factors for PMF in patients treated with NS+SRS. METHODS: We reviewed a prospective registry (2009 to 2020) and identified all patients treated with NS+SRS. Clinical, radiological, pathological and treatment factors were analyzed. PMF incidence was evaluated using a competing risks model and differences between cohorts were measured using the Fine-Gray method. RESULTS: 144 Patients were identified. Median age was 62 (23-90). PMF occurred in 22.2% (32/144) patients). Univariate analysis indicated female gender (HR 2.65, p=0.013), higher GPA status (HR 2.4, p<0.001), absence of prior radiation therapy (HR N/A, p=0.018), controlled extracranial disease (CED) (HR 3.46, p=0.0038), and contact with the pia/dura (HR 3.30, p=0.0053) as risk factors for PMF. Piecemeal (vs En-bloc) resection also trended towards correlation (HR 2.07, p=0.054). Multivariate Analysis identified contact with pia/dura (HR 3.51, p=0.0053), piecemeal resection (HR 2.38, p=0.027), and CED (HR 3.97, p=0.0016) as significant correlates to PMF. PMF correlated with reduced OS (HR 2.90, p<0.001) but was improved compared to patients who developed LMF (HR 10.15, p= p<0.001). CONCLUSIONS: PMF is an underrecognized phenomenon that correlates with pre-operative pia/dura contact and piecemeal resection in patients treated with NS+SRS for BM. While less morbid than LMF, it is a critical event that deserves increased vigilance and analysis. |
format | Online Article Text |
id | pubmed-9354221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93542212022-08-09 CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE Kalyvas, Aristotelis Gutierrez-Valencia, Enrique Weiss, Jessica O’ Halloran, Philip J Mohan, Nilesh Wong, Christine Conrad, Tatiana Millar, Barbara-Ann Laperriere, Normand Bernstein, Mark Zadeh, Gelareh Shultz, David Kongkham, Paul Neurooncol Adv Supplement Abstracts OBJECTIVE: Neurosurgery (NS) is an essential modality for large brain metastases (BM). As an adjuvant treatment, stereotactic radiosurgery (SRS) reduces neurocognitive toxicity without affecting post-treatment overall survival (OS) compared to whole brain radiation therapy. Pachymeningeal failure (PMF) beyond the SRS field is a relatively newly described entity, distinct from classical leptomeningeal failure (LMF), and unique to postoperative patients treated with adjuvant SRS. We sought to identify risk factors for PMF in patients treated with NS+SRS. METHODS: We reviewed a prospective registry (2009 to 2020) and identified all patients treated with NS+SRS. Clinical, radiological, pathological and treatment factors were analyzed. PMF incidence was evaluated using a competing risks model and differences between cohorts were measured using the Fine-Gray method. RESULTS: 144 Patients were identified. Median age was 62 (23-90). PMF occurred in 22.2% (32/144) patients). Univariate analysis indicated female gender (HR 2.65, p=0.013), higher GPA status (HR 2.4, p<0.001), absence of prior radiation therapy (HR N/A, p=0.018), controlled extracranial disease (CED) (HR 3.46, p=0.0038), and contact with the pia/dura (HR 3.30, p=0.0053) as risk factors for PMF. Piecemeal (vs En-bloc) resection also trended towards correlation (HR 2.07, p=0.054). Multivariate Analysis identified contact with pia/dura (HR 3.51, p=0.0053), piecemeal resection (HR 2.38, p=0.027), and CED (HR 3.97, p=0.0016) as significant correlates to PMF. PMF correlated with reduced OS (HR 2.90, p<0.001) but was improved compared to patients who developed LMF (HR 10.15, p= p<0.001). CONCLUSIONS: PMF is an underrecognized phenomenon that correlates with pre-operative pia/dura contact and piecemeal resection in patients treated with NS+SRS for BM. While less morbid than LMF, it is a critical event that deserves increased vigilance and analysis. Oxford University Press 2022-08-05 /pmc/articles/PMC9354221/ http://dx.doi.org/10.1093/noajnl/vdac078.040 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Abstracts Kalyvas, Aristotelis Gutierrez-Valencia, Enrique Weiss, Jessica O’ Halloran, Philip J Mohan, Nilesh Wong, Christine Conrad, Tatiana Millar, Barbara-Ann Laperriere, Normand Bernstein, Mark Zadeh, Gelareh Shultz, David Kongkham, Paul CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE |
title | CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE |
title_full | CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE |
title_fullStr | CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE |
title_full_unstemmed | CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE |
title_short | CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE |
title_sort | clrm-20 identifying risk factors and analyzing survival following pachymeningeal failure |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354221/ http://dx.doi.org/10.1093/noajnl/vdac078.040 |
work_keys_str_mv | AT kalyvasaristotelis clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT gutierrezvalenciaenrique clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT weissjessica clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT ohalloranphilipj clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT mohannilesh clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT wongchristine clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT conradtatiana clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT millarbarbaraann clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT laperrierenormand clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT bernsteinmark clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT zadehgelareh clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT shultzdavid clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure AT kongkhampaul clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure |